Jetstream Atherectomy with Paclitaxel-Coated Balloons: Two-Year Outcome of the Prospective Randomized JET-RANGER Study

Abstract

Background

The JET-RANGER study (NCT03206762) was a multicenter (11 US centers) randomized trial, core lab adjudicated, designed to demonstrate the superiority of Jetstream + Paclitaxel coated balloon (JET+PCB) versus angioplasty (PTA) + PCB in treating femoropopliteal (FP) arterial disease. The one-year primary endpoint of JET-RANGER has been recently published. The 2-year outcome data are presented in this report.

Methods

There were 43 patients who completed the 1-year follow-up. Two were lost to follow-up and one died prior to the 2-year follow-up, resulting in 40 patients. Fifteen patients were randomized to PTA+PCB and 25 patients to JET +PCB. Kaplan Meier Survival analysis was performed to estimate the freedom from TLR. Bailout stenting was not considered a TLR in this analysis. Statistical significance was determined by a p-value < 0.05.

Results

Freedom from TLR was similar between the 2 groups at 2 years. There was also no significant difference in the change of ABI between the PTA + PCB and JET + PCB from baseline at 6-months, (p-value = 0.7890), 1-year (p-value = 0.4070), and 2-year (p-value=0.7410). There was also no statistical difference between the JET + PCB and PTA + PCB arms for RCC improvement by one or more category, (p-value= 1.000). There were no minor or major amputations for either arm throughout the 2-year follow up. One JET + PCB patient died before the 2-year specified window.

Conclusion

JET + PCB had similar freedom from TLR and improvement in ABI and RCC at 2-year follow-up when compared to PTA + PCB with no difference in amputation or mortality between the 2 arms.

Clinical Trial Registration

NCT03206762.

Keywords:

• Jetstream
• atherectomy
• femoropopliteal
• vessel prepping
• drug coated balloons
• Ranger, In.PACT
• randomized trial
• dissections
• bailout stenting

Introduction

Vessel prepping with atherectomy improves technical and procedural outcomes and reduces bailout stenting.^1,2 Atherectomy however, has not been demonstrated to alter the long term outcome of femoropopliteal arterial disease treatment when compared to PTA alone.^2,3 Smaller randomized and observational data suggest that the combination of atherectomy and PCB is more effective than PCB alone in treating in-stent restenosis⁴ and possibly complex de novo arterial disease including severe calcium and long lesions.^5–8 These data are however not conclusive or powered to answer the question of added long term benefit of atherectomy and PCB when compared to PCB alone.

The Jetstream Atherectomy followed by Paclitaxel-Coated Balloons versus Balloon Angioplasty Followed by Paclitaxel-Coated Balloons (JET-RANGER Study) (NCT03206762) is a randomized trial of Jetstream atherectomy (JET) plus paclitaxel coated balloon (PCB) versus balloon angioplasty (PTA) plus PCB of the femoropopliteal artery (FP). The trial was stopped early because of poor enrolment due to the COVID-19 pandemic and the Food and Drug Administration (FDA) warning of an association of mortality with PCB. The one-year exploratory results were recently published⁹ and demonstrated that bailout stenting was significantly reduced in the JET + PCB arm when compared to the PTA + PCB arm (0 JET + DCB versus 50% PCB, P<0.0001) but target lesion revascularization (TLR) were statistically similar. In this report, we present the 2-year follow-up of the JET RANGER.

Methods

The JET-RANGER design, methods, procedural details and 1-year outcomes have been previously published.⁹ The study was approved by the central Advarra Independent Ethics Committee (IEC) with additional approval by the local Institutional Review Boards at the research sites when required. The study complies with the Declaration of Helsinki. Informed consent was obtained from the study participants prior to study commencement. Enrolment started in March of 2018 and the last one-year and 2-year patient follow-up were in April of 2021 and April 2022, respectively. The Clinical Events Committee (CEC) reviewed prespecified adverse events.

Secondary outcomes presented in this report include TLR, Change Rutherford Clinical Category (RCC) and Ankle-Brachial Index (ABI) at 2 years when compared to baseline and 1-year follow-up. A change of 0.15 or higher in the ABI was considered significant.

Statistical Methods

Analysis was performed per patient, per procedure, and per lesion. Descriptive analysis on all variables was done. Continuous data was presented as mean ± standard deviation [median]; Categorical data was given as count/sample (percentage). Anderson-Darling test was used to test for normality. Wilcoxon Signed test, Kruskal–Wallis test, one-sample and two-sample t-test, Mood’s Median test, Pearson’s Chi-Square test, and Fisher’s Exact test were used where appropriate. Survival Kaplan Meier Survival analysis was performed to estimate the Freedom from TLR with bailout stenting not considered as TLR. Comparison of Survival Curves was done by Wilcoxon. Statistical significance was determined by a p-value < 0.05. Software used was Minitab 21 (State College Pennsylvania, USA) and Cytel Studio 12 (Cambridge, Massachusetts, USA). Given the overall small number of patients enrolled, the analysis performed is considered exploratory. An intention to treat analysis was performed.

Results

There were 43 patients completed for the 1-year follow-up. Two were lost to follow-up and one died prior to the 2-year follow-up, resulting in 40 patients. Fifteen patients were randomized to PTA+PCB and 25 patients to JET + PCB. A higher procedural success and significantly less bailout stenting were seen in the JET+PCB arm as previously reported. Freedom from TLR, however, was 88% and 80% for the JET+PCB and PTA+PCB arms respectively at 2 years (p=0.3380) (Figure 1). There was also no significant difference in the change of ABI between the PTA + PCB and JET + PCB from baseline at 6-months, (p-value = 0.7890), 1-year (p-value = 0.4070), and 2-year (p-value=0.7410). There was also no statistical difference between the JET + PCB and PTA + PCB arms for RCC improvement by one or more category, (p-value= 1.000) (Figure 2). There were no minor or major amputations for either arm throughout the 2-year follow up. One (3.8%) JET + PCB patient died at 432 days post treatment from a cardiopulmonary arrest due to interstitial lung disease and mesenteric ischemia, probably unrelated to the procedure.

Figure 1 Kaplan-Meier for freedom from TLR at 2-year follow-up in the Jetstream and paclitaxel coated balloon versus the angioplasty and paclitaxel coated balloon arms.

Figure 2 Change in Rutherford Category in the Jetstream and paclitaxel coated balloon (JET + PCB) versus the angioplasty and paclitaxel coated balloon (PTA+PCB) arms.

Discussion

The 2-year follow up of the JET RANGER continues to show that PTA + PCB of de novo femoropopliteal lesions has similar freedom from TLR to the JET+PCB strategy but at the expense of half the patients in the PTA arm requiring bailout stenting mostly due to a higher residual narrowing.⁹ Atherectomy reduces the chance of severe dissections and the chance of bailout stenting as it has been demonstrated in several studies.^1,2,9 JET appears to be a favorable vessel prepping approach to treat complex de-novo femoropopliteal arterial disease prior to PCB in line of the strategy of leaving the least metal behind while maintaining similar long term outcomes to PTA+PCB. The cost-effectiveness of this approach has to be further studied.

Mortality with PCB has been raised as a concern with Katsanos et al¹⁰ and led to an FDA warning about the use of these devices. More recent data indicate that there was no significant increase in all-cause mortality with paclitaxel coated devices.^11–15 Given the small number of patients in our study, no definitive conclusions about mortality increase or decrease can be made with the Ranger or In.PACT balloons at 2 years.

In summary, this study shows that the strategy of JET+PCB yields excellent freedom from TLR at 2 years without the need for bailout stenting. Although PTA+PCB showed similar freedom from TLR at 2 years, this came at the cost of very high rate of bailout stenting when treating complex lesions with CTO, moderate to severe calcium and long lesions.

Limitations of the Study

The findings in this study are exploratory because a small number of patients have been evaluated. No definitive conclusions could be made. The study however confirms a high freedom from TLR for both JET+PCB and PTA+PCB at 2-year follow-up offering 2 different strategies to treat femoropopliteal de novo arterial disease. In addition, no safety issues of significance at 2-year follow-up were noted. A large, well-powered randomized trial of JET + PCB versus PTA + PCB with long term follow-up is needed to conclusively evaluate both strategies.

Data Sharing Statement

The authors do not intend to share individual deidentified data unless requested for a specific pre-specified analysis or for auditing purposes by regulatory bodies. Aggregate data will be released on clinicaltrials.gov and part of an indexed publication and will be accessible to public.

Disclosure

Dr Nicolas Shammas receives educational and research grants from Boston Scientific, Angiodynamics, VentureMed group, Phillips, Bard/BD and is on the speaker Bureau of Janssen, Merck, Lilly, Amgen, Esperion, Kiniksa, Boehringer Ingelheim. The other authors report no conflicts of interest in this work.

Acknowledgments

JET-RANGER one-year follow up was published in Vasc Health Risk Manag. 2022 Aug 2;18:603-615.

The following JET-RANGER investigators have contributed to the study by recruiting patients into this clinical trial or participated in the CEC committee or core laboratory:

Investigators

Lawrence Garcia, MD. Steward Saint Elizabeth, Boston MA

Nicholas Petruzzi, MD, Atlantic Medical, New Jersey

Mathew Wooster, MD, Medical University South Carolina, South Carolina

Jack Chamberlin, MD, Alexian Brothers Hospital, Illinois

William B. Eaves, MD, Endovascular Technologies, Louisianna

Richard Kovach, MD, Deborah Heart and Lung, Brown Mills, New Jersey

Mohammad Mehdi Ansari, MD, Texas Tech University Health Science, TX

Esteban Henao, MD, New Mexico Heart Institute, New Mexico

Faisal Latif, MD, VA Oklahoma, OK

April Nedeau, MD, Central Maine Medical Center, Maine

CEC Committee

Jon Robken, MD, Interventional Cardiology

Param Singh, MD, Interventional Cardiology

Vijay Ranjendran, MD, Interventional Cardiology

Additional information

Funding

The study was supported by an unrestricted grant from Boston Scientific.